ZDHHC22 and invasive breast carcinoma: In conclusion, we have revealed the expression pattern and pathological function of ZDHHC22 in BrCa, ZDHHC22-mediated mTOR palmitoylation, and inhibited the AKT signaling pathway to decrease malignant proliferation and endocrine resistance of BrCa cells.